The significance of detecting glucose transporter 1 and calretinin in serous effusions to differentiate between carcinoma cells and reactive mesothelial cells.

BACKGROUND: The cytologic evaluation of serous effusions to distinguish malignant cells from reactive mesothelial cells (RMCs)was an enormous challenge. The purpose of this study was to investigate the diagnostic value of glucose transporter 1 (GLUT1) and calretinin (CR) in serous effusions of patients with malignant and in order to significantly ameliorate the diagnostic accuracy. METHODS: The expressions of GLUT1 and CR were measured by streptavidin-peroxidase (S-P) immunocytochemical technique in serous effusions of 183 patients with malignant and in 95 patients with benign diseases. RESULTS: The positive ratio of GLUT1 was 91.8% (168/183) in serous effusions from patients with malignant and 5.3% (5/95) in benign diseases, they had a significant difference (P < .01). CR was expressed 89.5% (85/95) in benign diseases and 6.6% (12/183) in malignant, it also showed an important difference (P < 0.01). The combination of GLUT1 + CR revealed the best efficiency: the sensitivity and specificity were 100% and 98.9%, respectively. CONCLUSION: Immunocytochemical staining for GLUT1 and CR may be used as a complementary tool for the detection of malignant effusions and help to make a distinction between cancer cells and RMCs. The combination of GLUT1 and CR with immunocytochemistry stained can be achieved a higher diagnostic performance.

Expression and significance of MOC-31 and calretinin in pleural fluid of patients with lung cancer.

BACKGROUND: The cytologic assessment of pleural effusions to distinguish carcinoma cells from reactive mesothelial cells is particularly challenging. The aim of this study was to investigate the diagnostic value of monoclonal antibody (MOC-31) and calretinin in pleural fluid of patients with lung cancer to significantly improve the diagnostic accuracy. METHODS: The expressions of MOC-31 and calretinin were detected by means of S-P immunocytochemical technique in pleural effusions of patients with lung cancer (n = 92) and in patients with benign lung disease (n = 70). RESULTS: The positive rate of MOC-31 in pleural fluid was 90.2% (83/92) from patients with lung cancer and 2.9% (2/70) from patients with benign lung diseases, showing a significant difference (P < 0.01). Calretinin was expressed 87.1% (61/70) in benign lung diseases and 6.5% (6/92) in lung cancer, also showing a significant difference (P < 0.01). The optimal combination for assay was MOC-31 + calretinin: Sensitivity and specificity were 100 and 98.6%, respectively. CONCLUSION: MOC-31 and calretinin are of important clinical value for diagnosing and differentially diagnosing the cancer cells in pleural fluid of patients with lung cancer.

Aberration of the Wnt signaling pathway in pulmonary fatal adenocarcinoma: a case report.

We report a case of a 58-year-old woman showed a homogeneous well-defined perihilar mass in the right upper lobe and fully surrounded by aerated parenchyma at computed tomography (CT). A right upper lobectomy with mediastinal lymph node sampling was performed. A pathologic diagnosis of well-differentiated fetal adenocarcinoma of the lung was made and staged as T2bN0M0. For the expression of Wnt signaling pathway molecules, positive expressions of Wnt1, ß-catenin, c-Myc, Cyclin D1and MMP7 were especially prominent in budding solid nests, but not in glandular structures. The nuclear/cytoplasmic localization of ß-catenin accompanied upregulation of Wnt signaling pathway molecules in budding solid nests. These results demonstrated that elevated nuclear/cytoplasmic expression of ß-catenin in fatal adenocarcinoma might be regulated by the Wnt signaling pathway.

[Expression and clinical significance of CD40 in diffuse large B-cell lymphoma].

OBJECTIVE: To study the expression of CD40 in diffuse large B-cell lymphoma (DLBCL) and its relationship with various clinical parameters, pathologic findings and prognostic data. METHODS: The clinical information of 87 patients with DLBCL diagnosed in Jilin Province Cancer Hospital during the period from January, 2008 to october, 2012 was retrospectively reviewed. Immunohistochemical study using SP technique for CD40 was carried out. The correlation between clinicopathologic findings, CD40 expression and survival data was analyzed using statistical software. RESULTS: Cases of CD40-positive DLBCL were characterized by lower age group, early clinical stage, less extranodal involvement, lower IPI index and lower ECOG score. However, there was no significant correlation between gender of patients and site of involvement (P = 0.141 and 0.729). The overall survival of patients with CD40-positive DLBCL was significantly higher than that in patients with CD40-negative DLBCL. One-way analysis of variance showed that the prognosis of DLBCL was closely associated with CD40 expression, age of patients, ECOG score, IPI index, extranodal involvement and LDH level (P < 0.05, respectively). Stratified analysis showed that CD40-positive DLBCL carried a better prognosis, irrespective of other immunophenotyping results. COX model multivariate analysis showed that the expression of CD40 closely correlated with other immunophenotyping results, ECOG score, clinical staging, treatment regimen and prognosis (P < 0.05). CONCLUSION: The expression of CD40 is a favorable prognostic indicator in patients with DLCBL.